Incomplete Passage Of Stool — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for incomplete passage of stool. 2 active patents protecting 1 drugs from 1+ originators. First major cliff: 2039. Daily refresh.

1
Approved drugs
2
Active US patents
55/100
Avg vulnerability
—
Annual revenue covered

Originators in Incomplete Passage Of Stool

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Nesher Pharms 2 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating incomplete passage of stool. Each bar = one year. Y-axis scaled to peak year (2 patents).

2
39

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Micro-K 10
POTASSIUM CHLORIDE
 Nesher Pharms 2 55 — 2039-03-07

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
12539314 Micro-K 10 formulation 55 2039-03-07
12539314 Micro-K 10 formulation 55 2039-03-07

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
12539314 Micro-K 10 formulation 55 2039-03-07
12539314 Micro-K 10 formulation 55 2039-03-07

Related